Vertex Pharmaceuticals
VRTX
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
The Motley Fool • 1 day ago • VRTX
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030Seeking Alpha • 2 days ago • VRTX
Vertex Pharmaceuticals Incorporated (VRTX) Management presents at Cantor Global Healthcare Conference (Transcript)Zacks Investment Research • 2 days ago • VRTX
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to KnowSeeking Alpha • 4 days ago • VRTX
Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain DrugThe Motley Fool • 5 days ago • VRTX
3 Stocks to Buy and Hold ForeverCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.